Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$55.11|
|52-week range||$43.00 - $151.80|
|50-day moving average||$63.29|
|200-day moving average||$84.10|
|Wall St. target price||$72.64|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-18.33%|
|1 month (2021-08-18)||-16.54%|
|3 months (2021-06-18)||-11.03%|
|6 months (2021-03-18)||-38.44%|
|1 year (2020-09-18)||5.80%|
|2 years (2019-09-14)||N/A|
|3 years (2018-09-14)||N/A|
|5 years (2016-09-14)||N/A|
|Revenue TTM||$48.9 million|
|Gross profit TTM||$34.7 million|
|Return on assets TTM||-10.17%|
|Return on equity TTM||-38.63%|
|Market capitalisation||$12.6 billion|
TTM: trailing 12 months
There are currently 4.5 million CureVac N-V shares held short by investors – that's known as CureVac N-V's "short interest". This figure is 12.4% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting CureVac N-V shares can be evaluated.
CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V shares currently shorted divided by the average quantity of CureVac N-V shares traded daily (recently around 728954.6474359). CureVac N-V's SIR currently stands at 6.24. In other words for every 100,000 CureVac N-V shares traded daily on the market, roughly 6240 shares are currently held short.
However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V shares, or, against the total number of tradable CureVac N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CureVac N-V shares in existence, roughly 20 shares are currently held short) or 0.0565% of the tradable shares (for every 100,000 tradable CureVac N-V shares, roughly 57 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CureVac N-V.
Find out more about how you can short CureVac N-V stock.
We're not expecting CureVac N-V to pay a dividend over the next 12 months.
CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.